International Journal of Clinical Practice · 2005 · 21 citations · 28 references
PharmacyPharmacoeconomicsPharmacotherapyClinical PharmacologyCost-effectiveness AnalysisPharmacoeconomic ModelingCost-effectiveness ComparisonCost-effectiveness ModelingEconomic EvaluationEsophageal DiseasesGastroesophageal Reflux DiseasePharmacoeconomic EvaluationContinuous Course Of TreatmentDirect CostsDirect Treatment CostsGastroesophageal Reflux Disease PharmacotherapyMedication Cost BurdenMedication Cost ManagementOn-demand TreatmentPharmacologic Therapy For Gerd
This study assesses the difference in direct medical costs between on-demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once-daily and continuous treatment with ranitidine 150 mg twice-daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty-one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000-2001. The total direct medical costs of each strategy were 171.9 Euros for on-demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on-demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on-demand and continuous treatment strategies with esomeprazole were found to be cost-effective, compared with ranitidine.
28
An evidence-based appraisal of reflux disease management — the Genval Workshop Report
John Dent, Johan G. Brun, A. Mark Fendrick et al. · Gut · 1998 · 890 citations · Full text
Joel E. Richter, Peter J. Kahrilas, John F. Johanson et al. · The American Journal of Gastroenterology · 2001 · 394 citations